Lupin plans to launch around 25 products in US in FY17

Drug major Lupin is planning to launch around 25 products in the US market in FY17. Apart from the Gavis portfolio, Fortamet and Glumetza, the company is expecting to launch products like Minastrin and Epzicom. The Mumbai-based firm is planning to go ahead with launches on the dermatology front this year.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.